1. Academic Validation
  2. Probing Isosteric Replacement for Immunoadjuvant Design: Bis-Aryl Triazole Trehalolipids are Mincle Agonists

Probing Isosteric Replacement for Immunoadjuvant Design: Bis-Aryl Triazole Trehalolipids are Mincle Agonists

  • ACS Med Chem Lett. 2024 May 21;15(6):899-905. doi: 10.1021/acsmedchemlett.4c00100.
Michael J Foster 1 Emma M Dangerfield 2 Mattie S M Timmer 2 Bridget L Stocker 2 Brendan L Wilkinson 1
Affiliations

Affiliations

  • 1 School of Science and Technology, University of New England, Armidale 2351, Australia.
  • 2 School of Chemical and Physical Sciences, Victoria University of Wellington, P.O. Box 600, Wellington 6140, New Zealand.
Abstract

Herein, we report the modular synthesis and immunological activity of seven bis-aryl triazole trehalolipids (1a-1g) as Brartemicin analogs. The compounds comprised one or two octyloxy (C8) alkyl chains and were synthesized using the venerable CuAAc reaction between the respective aryl acetylenes and a trehalose diazide. A Mincle reporter cell assay revealed that all lipidated analogs activated Mincle. Two compounds, 1c and 1d, produced strong Mincle-dependent immune responses in vitro. The activity was dependent on the degree of alkylation and regiochemistry, with 1c and 1d showing significantly increased IL-1β production in vitro compared to monoalkylated compounds and dialkylated compounds lacking ortho substitution. Molecular docking of 1c positioned the triazole in proximity to Arg-183, which may offer additional interactions that could explain the binding affinity for this class of ligand. These findings demonstrate the capability of triazole-linked Brartemicin analogs as Mincle-mediated Th1/Th17 vaccine adjuvants.

Figures
Products